by Wiysonge CS, Bradley HA, Volmink J et al.
Cochrane Database of Systematic Reviews 2017, Issue 1
Most outcome randomised controlled trials (RCTs) on beta-blockers as initial therapy for hypertension have high risk of bias. Atenolol was the beta-blocker most used. Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest cardiovascular disease (CVD) reductions and little or no effects on mortality. These beta-blocker effects are inferior to those of other antihypertensive drugs. Further research should be of high quality and should explore whether there are differences between different subtypes of beta-blockers or whether beta-blockers have differential effects on younger and older people.